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GYNECOLOGYSystematic review and metaanalysis of
genetic association studies of urinary
symptoms and prolapse in women
Rufus Cartwright, MA, MD(res), MRCOG; Anna C. Kirby, MD; Kari A. O. Tikkinen, MD, PhD;
Altaf Mangera, MRCS, MD; Gans Thiagamoorthy, MRCOG; Prabhakar Rajan, MRCS, PhD;
Jori Pesonen, MD; Chris Ambrose, MBBS; Juan Gonzalez-Maffe, PhD;
Phillip Bennett, MD, PhD, FRCOG; Tom Palmer, PhD; Andrew Walley, MA, DPhil;
Marjo-Riitta Ja¨rvelin, MD, MSc, PhD; Chris Chapple, BSc, MD, FRCS(Urol), FEBU;
Vik Khullar, MD, FRCOGOBJECTIVE: Family studies and twin studies demonstrate that lower RESULTS: In pooled analysis, the rs4994 polymorphism of the ADRB3
urinary tract symptoms and pelvic organ prolapse are heritable. This
review aimed to identify genetic polymorphisms tested for an association
with lower urinary tract symptoms or prolapse, and to assess the
strength, consistency, and risk of bias among reported associations.
STUDY DESIGN: PubMed and HuGE Navigator were searched up to
May 1, 2014, using a combination of genetic and phenotype key
words, including “nocturia,” “incontinence,” “overactive bladder,”
“prolapse,” and “enuresis.” Major genetics, urology, and gynecology
conference abstracts were searched from 2005 through 2013. We
screened 889 abstracts, and retrieved 78 full texts. In all, 27 published
and 7 unpublished studies provided data on polymorphisms in or near
32 different genes. Fixed and random effects metaanalyses were
conducted using codominant models of inheritance. We assessed the
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FIGURE 1
Research Gynecology ajog.orgemale pelvic ﬂoor disorders, anFlowchart outlining literature search and article evaluation process
a American Society of Human Genetics, American Urological Association, American Urogynecologic Society, European Association of
Urology, European Society of Human Genetics, International Continence Society, International Urogynecological Association, and Society
of Gynecologic Surgeons abstracts 2005 through 2014, using online search interfaces and/or full text search of abstract book PDFs;
b Includes studies enrolling only men (n ¼ 122), enrolling only children (n ¼ 2), narrative reviews or letters (n ¼ 12), inapplicable
phenotype (n¼ 2), and other study designs including pharmacogenetic studies, gene expression studies, or methylation studies (n¼ 8);
c Authors contacted by email for additional data from 18 studies.
Cartwright. Genetic association studies of LUTS and POP. Am J Obstet Gynecol 2015.F umbrella term including urinary
incontinence, bladder storage symp-
toms, and pelvic organ prolapse (POP)
are highly prevalent.1,2 Almost one
quarter of adult women report at least
one clinically meaningful pelvic ﬂoor
disorder,1,3 with frequent overlap be-
tween conditions.4,5 These conditions
are associated with a range of comor-
bidities,6-8 and have a substantial impact
on quality of life.9-11 There are strong
associations with both age and obesity,12-
15 and thus the population burden of
these conditions will increase with future
demographic shifts.
The existence of inherited risk fac-
tors for pelvic ﬂoor disorders has been
recognized for more than 150 years,16
and there is clear familial aggregation
for these conditions. Having an affected
ﬁrst-degree relative with incontinence
or prolapse is associated with an
approximately 2- to 3-fold increased
risk of developing either condition,
with effects measurable for all major
subtypes of incontinence, and for
anterior, apical, and posterior
compartment prolapse.17-21 A relevant
family history is associated with both
earlier onset, and more rapidly pro-
gressive symptoms.22,23
Family studies provide limited in-
formation on heritability, as they do not
control for shared exposure to envi-
ronmental risk factors. Twin studies
have been used to formally quantify the
heritability of lower urinary tract
symptoms (LUTS) or prolapse. In a
sample of 16,886 Swedish twins aged
>50 years, heritability was estimated as
41% for stress incontinence surgery,
and 43% for prolapse surgery.24 Simi-
larly for twins aged 20-46 years from the
same cohort (n ¼ 4550), heritability
was estimated as 34% for stress incon-
tinence, 37% for urgency incontinence,
and 48% for nocturia.25 Among a
cohort of 2336 women enrolled in the
Danish Twin Register,26 heritability
ranged with age from 42-49% for ur-
gency incontinence, 27-55% for mixed
incontinence, and up to 39% for stress
incontinence.
Identiﬁcation of the genetic variants
underlying the heritability of these199.e2 American Journal of Obstetrics& Gynecolconditions would provide useful
markers for clinical risk, prognosis, and
treatment response. In addition, how-
ever, the insights provided should help
explain the pathogenesis of these
complex diseases, potentially offering
new drug targets and preventative
strategies. The aim of this systematic
review was therefore to assess which
candidate polymorphisms and/or
candidate genes had been tested for
an association with POP or LUTS in
women, and to assess the strength,
consistency, and potential for bias
among published associations.ogy FEBRUARY 2015MATERIALS AND METHODS
Eligibility criteria
The review protocol was prospec-
tively registered (PROSPERO 2011:
CRD42012001983).27 We prespeciﬁed
inclusion of both case-control and cross-
sectional designs, with both population-
based samples and other sampling
methods. We included association studies
testing for any genetic polymorphism
at the nucleotide level, including single-
nucleotide polymorphisms (SNPs), de-
letions, duplications, and copy-number
variants, but excluded larger microscopic
variants at the karyotype level.
TABLE 1
Included studies
Study Journal and year Country
Descent,
ethnicity, racea Gene symbols(s)
Polymorphism(s)
dbSNP ID Case definition
Control
definition
Cases
genotyped, n
Controls
genotyped, n
Allen-Brady
et al76
Obstet Gynecol 2011 United States,
The Netherlands
White and
Northern
European
descent
LINC0108b
ZFAT
Intergenic
Intergenic
Intergenic
COL18A1
rs1455311
rs1036819
rs430794
rs8027714
rs1810636
rs2236479
Surgically
treated/recurrent
POP with family
history
Population
controls
191 3036
Campeau
et al59
Neurourol Urodyn
2011 (ICS abstract)
United States Not stated MMP1 rs1144393
rs498186
rs473509
Surgically treated
POP
Hospital controls
“without POP”
63 93
Chen et al55 Am J Obstet Gynecol
2010
United States African
American
and Caucasian
LAMC1 rs10911193
rs20563
rs20558
POP stage >II POP stage <II 165 246
Chen et al66 Int Urogynecol J
2008
Taiwan Taiwanese ESR1 rs17847075
rs2207647
rs2234693
rs3798577
rs2228480
POPQ 2 POPQ <2 88 153
Chen et al68 Acta Obstet Gynecol
2009
Taiwan Taiwanese PGR rs500760
rs484389
POPQ 2 POPQ <2 87 150
Chen et al78 Am Soc Hum Genet
2013
United States African
American
and Hispanic
American
PRCP b rs2086297 Symptomatic SUI No SUI z3343 z8183
Chen et al66 Int Urogynecol J
2008
Taiwan Taiwanese COL3A1 rs1800255
rs1801184
POPQ 2 POPQ <2 84 147
Chen et al64 Eur J Obstet Gynecol
2010
Taiwan Taiwanese MMP9 rs3918242
rs17576
rs2250889
POPQ 2 POPQ <2 92 152
Chen et al67 Eur J Obstet Gynecol
2008
Taiwan Taiwanese ESR2 rs2987983
rs1271572
rs944459
rs1256049
rs1255998
POPQ 2 POPQ <2 69 141
Cho et al45 Yonsei Med J 2009 Korea Korean COL1A1 rs1800012 Surgically treated
POPQ 3
POPQ ¼ 0 15 15
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TABLE 1
Included studies (continued)
Study Journal and year Country
Descent,
ethnicity, racea Gene symbols(s)
Polymorphism(s)
dbSNP ID Case definition
Control
definition
Cases
genotyped, n
Controls
genotyped, n
Choy et al69 ICS abstract 2007 Hong Kong Chinese EDN1 rs5370
rs10478694
POPQ 2 Hospital “normal’’
controls and
HapMap Han
Chinese controls
60 (rs5370)
and 67
(rs10478694)
210
Cornu et al70 World J Urol 2011 France Caucasian ESR1
CYP17A1
CYP19A1
AR
rs2234693
rs743572
rs60271534
CAG repeat
Treated for UI
(30 UUI, 107 SUI)
No UI or OAB 121 66
Feiner et al42 Int Urogynecol J
2009
Israel Caucasian or
Ashkenazi-
Jewish
COL1a1 rs1800012 POPQ 3 POPQ <2 36 36
Ferrari et al44 Arch Gynecol Obstet
2012
Italy Italian COL1a1
MMP9
MMP1
MMP3
rs1800012
rs3918242
rs1799750
rs3025058
POPQ 2 POPQ <2 137 96
Ferreira et al38 Am J Obstet Gynecol
2011
Brazil White or
nonwhite
ADRB3 rs4994 Symptomatic OAB
without severe
SUI
No LUTS 49 169
Ferrell et al75 Reprod Sci 2009 United States African
American or
Caucasian
LOXL1 rs16958477 POP stage II POP stage <II 137 130
Fu et al56 J Urol 2009 (AUA
abstract)
United States Not stated LAMC1
LOXL1
rs10911193 POP stage III No POP or UI 61 33
Honda et al37 Neurourol Urodyn
2014
Japan Japanese ADRb3 rs4994 Symptomatic OAB No OAB 100 101
Jeon et al51 J Urol 2009 Korea Korean COL3a1 rs111929073 POPQ 2 POPQ <2 and no
SUI
36 36
Kim et al74 Eur J Obstet Gynecol
Reprod Biol 2014
Korea Korean GSTM1
GSTT1
GSTP1
Null
Null
rs1695
POPQ 3 POPQ <2 189 156
Kim et al73 Menopause 2014 Korea Korean PARP1 rs1136410 POPQ 3 POPQ <2 185 155
Lince et al50 Int Urogynecol J
2014
The Netherlands z99% Dutch COL3a1 rs1800255 POPQ 2 POPQ <2 272 82
Martins et al52 Neurourol Urodyn
2011
Brazil White or
nonwhite
COL3a1 rs111929073 POP stage III POP stage <II 107 209
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TABLE 1
Included studies (continued)
Study Journal and year Country
Descent,
ethnicity, racea Gene symbols(s)
Polymorphism(s)
dbSNP ID Case definition
Control
definition
Cases
genotyped, n
Controls
genotyped, n
Noronha
et al71
J Investig Med 2010 Brazil Predominant
European/white
HTR2A rs6313 Symptomatic UI Self-reported
continent women,
and population
controls
68 849
Ozbek et al72 J Obstet Gynaecol
Res 2013
Turkey Caucasian LOXL1 rs2165241
rs3825942
rs1048661
Symptomatic SUI No UI 93 75
Rodrigues
et al41
Int Urogynecol J
2008
Brazil White or
nonwhite
COL1a1 rs1800012 POP stage III POP stage<II and
no SUI
107 209
Romero and
Jamison65
J Pelv Med Surg
2008
United States White MMP1
MMP2
MMP3
MMP8
MMP9
MMP10
MMP11
TIMP1
TIMP3
rs2071230
rs7201
rs679620
rs35866072
rs17576
rs17435959
rs738789
rs4898
rs2016293
POPQ 3 POPQ <2 and no
UI
45 38
Sioutis et al47 Int Urogynecol J
2011
Greece Greek COL1a1 rs1800012 SUI confirmed
with urodynamics
and positive pad
test, and
postmenopausal
Healthy
postmenopausal
45 45
Skorupski43 Int Urogynecol J
2009 (IUGA abstract)
Poland Polish COL1a1 rs1800012 POPQ 2 POPQ <2 and no
UI
120 97
Skorupski
et al46
Am J Obstet Gynecol
2006
Poland Polish COL1a1 rs1800012 SUI confirmed
with urodynamics
and positive pad
test
POPQ <2 and no
UI
50 50
Skorupski
et al61
Ginekol Polska 2010 Poland Polish MMP1
MMP3
rs1799750
rs3025058
POPQ 2 POPQ <2 132 133
Takeda et al36 ICS Abstract 2002 Japan Japanese ADRb3
ADRA1A
rs4994
rs1048101
Any LUTS
(includes mixed
group of women
and men)
No LUTS 27 17
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TABLE 1
Included studies (continued)
Study Journal and year Country
Descent,
ethnicity, racea Gene symbols(s)
Polymorphism(s)
dbSNP ID Case definition
Control
definition
Cases
genotyped, n
Controls
genotyped, n
Velez Edwards
et al77
Am Soc Hum Gen
2013
United States African
American and
Hispanic
American
CPEb
Intergenic
rs28573326
rs113518633
POP stage I POP stage ¼ 0 1427 1274
Vishwajit
et al60
ICS abstract 2009 United States Not stated MMP1 rs1799750 SUI with varying
POP
Neither SUI nor
POP
40 15
Wu et al54 Am J Obstet Gynecol
2012
United States Non-Hispanic
white
LAMC1 rs10911193
rs1413390
rs20558
rs20563
rs10911206
rs2296291
rs12041030
rs12739316
rs3768617
rs2483675
rs10911211
rs41475048
rs1058177
rs12073936
POPQ 3 POPQ <2 239 197
Wu et al63 Obstet Gynecol 2012 United States Non-Hispanic
white
MMP9 rs3918253
rs3918256
rs3918278
rs17576
rs2274755
rs17577
rs2236416
rs3787268
POPQ 3 POPQ <2 239 197
AUA, American Urological Association; ICS, International Continence Society; IUGA, International Urogynecological Association; LUTS, lower urinary tract symptoms; OAB, overactive bladder; POP, pelvic organ prolapse; POPQ, Pelvic Organ Prolapse Quantification
system; SNP, single-nucleotide polymorphism; SUI, stress urinary incontinence; UI, urinary incontinence; UUI, urge urinary incontinence.
a Assessments of descent/ethnicity/race as specified in primary publications, or from additional data from authors, or assumed for countries with low ethnic heterogeneity including Taiwan, Korea, and Japan; b Genome-wide significant genes (P<5 10-8) reported
in genome-wide association study.
Cartwright. Genetic association studies of LUTS and POP. Am J Obstet Gynecol 2015.
R
esea
r
c
h
G
ynecology
ajo
g.o
rg
199.e6
A
m
erican
Journalof
O
bstetrics
&
G
ynecology
FEB
R
U
A
R
Y
2015
FIGURE 2
Forest plot of rs4994 SNP of ADRB3 and overactive bladder
Forest plot of studies37,38 reporting associations between rs4994 single-nucleotide polymorphism
(SNP)* of beta 3 adrenoceptor gene and overactive bladder. *RefSNP alleles C/T. Plot presented as
risk associated with minor allele C.
CI, confidence interval; OR, odds ratio.
Cartwright. Genetic association studies of LUTS and POP. Am J Obstet Gynecol 2015.
ajog.org Gynecology ResearchThere are no gold standard diagnostic
methods for either stress urinary in-
continence (SUI) or other LUTS, as these
are largely subjective symptomatic di-
agnoses. For POP, validated staging sys-
tems, including POP Quantiﬁcation,
have been widely used, but again there is
no universally accepted criterion for
diagnosis. We therefore expected to
accept diagnostic criteria for LUTS and
prolapse as speciﬁed within each study.
In view of heterogeneity in deﬁnitions
across studies, we tested for heteroge-
neity between studies with different
criteria in different settings. We accepted
deﬁnitions based on symptom ques-
tionnaires, clinical examination, urody-
namics, or other validated assessments.
We considered the population of interest
as women aged 18 years.
Search strategy
We combined searches from PubMed,
HuGE Navigator, and an extensive se-
lection of genetic, urological, and uro-
gynecological conference reports. We
searched PubMed up to May 1, 2014,
without language restrictions, using a
combination of genetic and phenotypekey words andMedical Subject Headings
(MeSH) terms: (polymorphism OR SNP
ORCNVOR “copy number variation”OR
mutation OR genetic OR chromosome OR
VNTR OR InDel OR microsatellite) AND
(nocturia OR LUTS OR incontinence OR
urgency OR “overactive bladder” OR
prolapse OR “Lower Urinary Tract
Symptoms”[Mesh] OR “Urinary Incon-
tinence”[MeSH] OR “enuresis”[Mesh]
OR “Pelvic Organ Prolapse”[MeSH])
NOT mitral NOT carcinoma[Title] NOT
cancer[Title] NOT (animals[mh] NOT
humans[mh]).
We searched HuGE Navigator, also
through to May 1, 2014, using the
following phenotype indexing terms:
(“urination disorders” OR “urinary in-
continence” OR “pelvic organ prolapse”).
In addition we searched conference
abstracts for annual meetings of the
American Society of Human Genetics,
American Urological Association, Amer-
ican Urogynecologic Society, European
Association of Urology, European Society
of Human Genetics, International Conti-
nence Society, International Urogyneco-
logical Association, and Society of
Gynecologic Surgeons 2005 through 2013.FEBRUARY 2015 AmeriScreening and data extraction
We developed standardized data forms
for this study, and conducted pilot
screening and data extraction training
exercises to achieve a high level of
consensus between reviewers. All
screening and data extraction was then
performed independently and in dupli-
cate by methodologically trained re-
viewers. Reviewers screened study
reports by ﬁrst screening titles and ab-
stracts to select papers for full-text
assessment, then screening full-text pa-
pers to conﬁrm eligibility of the articles.
Screening discrepancies were resolved by
adjudication. We hand searched refer-
ence lists of all included articles, applying
the same standardized screening process.
When >1 report was identiﬁed for the
same association in the same study
population, we included the publication
with the largest sample size.
We contacted study authors by email,
with a reminder after 1 month, for
clariﬁcations, additional information
about methodology, and additional
subgroup analyses where necessary. Data
extracted included information on the
setting for each study, details of the
sampling strategy and sampled pop-
ulations (age, parity, ethnic/racial
composition, and body mass index), the
overall sample size and proportion gen-
otyped, the outcome assessments used
and phenotypic deﬁnitions, the geno-
typing method employed, and the gen-
otyping quality control applied. Where
possible we extracted or requested from
authors full genotype frequencies among
both cases and controls.Statistical analysis and risk of bias
assessments
For polymorphisms assessed in 2
studies for the same phenotype assessed
with similar case deﬁnitions, we con-
ducted ﬁxed or random effects meta-
analyses as appropriate using the
Metan28 package (Stata 12.1; StataCorp,
College Station, TX). In all cases, we
worked from genotype or allele fre-
quencies, rather than using precalcu-
lated effect sizes. We did not pool data
from studies with mixed male and fe-
male samples, unless results stratiﬁed bycan Journal of Obstetrics& Gynecology 199.e7
TABLE 2
Interim Venice assessments of epidemiological credibility for each metaanalysis
Gene SNP Phenotype
Studies,
n
Sample
with
minor
allelea
Pooled
OR I2 %
Deviation
from
HWEb
Proteus
effect
Harbord
test
P value
Funnel
plot Genotyping QC
Risk of
population
stratification
Venice
rating
Overall
credibility
ADRB3 rs4994 OAB 2 136 2.46 0.0 None None n/a n/a Not reported Yes38c BBB Moderate
COL1A1 rs1800012 SUI 2 92 2.09 0.0 Yes46 None n/a n/a Not reported Low CBC Weak
POP 4 249 1.33 0.0 None None .88 Symmetric Not reported Yes41,42c BBB Moderate
COL3A1 rs1800255 POP 2 257 1.19 0.0 None Yes n/a n/a Not reported49/
appropriate50
None BCB Weak
rs111929073 POP 2 115 0.56 83.7 None None n/a n/a Not reported Yes52c BCB Weak
LAMC1 rs10911193 POP 4 218 1.12 0.0 None None .97 Symmetric Appropriate54,55/
not reported56
Low BCB Weak
rs20563 POP 3 525 1.12 0.0 None None .86 Symmetric Appropriate Low BCA Weak
rs20558 POP 3 551 1.12 0.0 None None .93 Symmetric Appropriate Low BCA Weak
MMP1 rs1799750 POP 2 234 0.83 74.9 Yes61 Yes n/a n/a Not reported Low BCC Weak
SUI 2 150 0.88 3.4 None None n/a n/a Not reported Yes60c BCC Weak
MMP3 rs3025058 POP 2 381 1.11 0.0 Yes61 None n/a n/a Not reported Low BCC Weak
MMP9 rs3918242 POP 2 99 1.25 0.0 None None n/a n/a Not reported Low CCC Weak
rs17576 POP 3 473 1.05 68.9 None None .72 Symmetric Not reported57/
appropriate54
Low BCB Weak
Three-letter code corresponds to A through C ratings of amount of evidence, its consistency, and its protection from bias (Supplementary Figure).
HWE, Hardy Weinberg Equilibrium; OAB, overactive bladder; OR, odds ratio; POP, pelvic organ prolapse; QC, quality control; SNP, single-nucleotide polymorphism; SUI, stress urinary incontinence.
a Pooled sample size of participants with minor allele; b Checked in controls and whole population, and metaanalysis rechecked excluding studies with significant departure; c Studies each include populations with mixed descent groups without reported adjustment.
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FIGURE 3
Forest plot of studies of rs1800013 SNP of COL1A1
Forest plot of studies41-44,46-47 reporting associations between rs1800012 single-nucleotide poly-
morphism (SNP)* of collagen type 1 alpha 1 gene and either stress urinary incontinence (SUI) or pelvic
organ prolapse (POP). *RefSNP alleles G/T. Plot presented as risk associated with minor allele T.
CI, confidence interval; OR, odds ratio.
Cartwright. Genetic association studies of LUTS and POP. Am J Obstet Gynecol 2015.
ajog.org Gynecology Researchsex were available. We did not pool data
from studies with composite case deﬁ-
nitions (ie, any urinary incontinence)
with those with simple case deﬁnitions
(ie, SUI). In the absence of a clear
rationale supporting any speciﬁc model
of inheritance, we used the allelic asso-
ciation test/codominant models of in-
heritance for all polymorphisms. We
assessed the credibility of pooled asso-
ciations using the interim Venice
criteria29 (Appendix; Supplementary
Figure). We used the I2 statistic as a
measure of between study heterogeneity.
We recalculated the power of each
study, and retested for departure from
Hardy-Weinberg equilibrium. We made
assessments of risk of bias in phenotype
deﬁnitions, genotyping, and population
stratiﬁcation. We used the Harbord
test of funnel plot asymmetry, and
the signiﬁcance chasing bias test30 to
investigate possible reporting biases.
Reporting of this review complies
with recommendations both of the
HuGE Handbook, and the PRISMA
statement.31,32
RESULTS
Search outcomes
We screened 889 abstracts, and retrieved
78 full texts (Figure 1). In all, 27 pub-
lished studies and 7 unpublished studies
provided data (Table 1) regarding poly-
morphisms in or near 32 different genes
(Supplementary Table 1). Most research
interest has focused on variation in
genes implicated in extracellular matrix
organization and disassembly, with
particular focus on collagen and metal-
loendopeptidase genes (Supplementary
Table 2). A number of studies also
addressed a variety of steroid hormone
receptor genes. All studies investigated
POP, SUI, or overactive bladder, with
no available data on other individual
LUTS.
Quantitative syntheses were possible
for 11 polymorphisms in or near 7
genes: beta 3 adrenoceptor (ADRB3);
collagen, type I, alpha 1 (COL1A1);
collagen, type 3, alpha 1 (COL3A1);
laminin gamma 1 (LAMC1); matrix
metalloproteinase-1 (MMP1); matrix
metalloproteinase-3 (MMP3); and ma-
trix metalloproteinase-9 (MMP9).ADRB3
Variation in the beta-3 adrenoceptor,
particularly of the rs4994 SNP, also
known as Trp64Arg, has been extensively
investigated in association with obesity,
type 2 diabetes mellitus, and other
metabolic syndrome phenotypes. The
beta-3 adrenoceptor is highly expressed
in bladder, and mediates detrusor mus-
cle relaxation.33 A beta-3 adrenoceptor
agonist has recently been approved for
treatment of overactive bladder symp-
toms.34,35 One conference abstract,36
and 2 published papers37,38 provided
relevant information on the common
rs4994 missense mutation, of which 2
could be included in metaanalysis. In the
initial report, in a heterogeneous Japa-
nese sample of 13 men and 31 women,
with diverse urological pathologies
including neurogenic bladder and
benign prostatic hyperplasia, the rs4994
SNP was not associated with LUTS
(odds ratio [OR], 1.20; 95% conﬁdence
interval [CI], 0.32e4.47).36 Results were
not available stratiﬁed by sex, and couldFEBRUARY 2015 Amerinot be included in quantitative synthesis.
Subsequent reports used larger samples of
Japanese women,37 and Brazilian
women38 (Table 1), and looked specif-
ically at the overactive bladder phenotype,
ﬁnding a large effect size (pooled OR,
2.46; 95%CI, 1.67e3.60) (Figure 2), with
no heterogeneity. Despite a lack of infor-
mation about genotyping quality control
(QC), and some risk of population strat-
iﬁcation, this large effect size confers
some protection from bias, providing
Venice grading BBB, or moderate epide-
miological credibility (Table 2).
COL1A1
rs1800012 also known as the Sp1-binding
site polymorphism of collagen, type I,
alpha 1, modiﬁes transcription factor
binding and gene expression. It has been
most extensively studied in association
with osteoporosis, where the minor allele
is modestly associated with reduced bone
mineral density and increased fracture
risk.39 Collagen, type I, alpha 1 is a major
structural component of the vaginalcan Journal of Obstetrics& Gynecology 199.e9
FIGURE 4
Forest plot of COL3A1 SNPs and prolapse
Forest plot of studies49-52 reporting associations between rs1800255* and rs111929073* single-
nucleotide polymorphisms (SNPs) of collagen type 3, alpha 1 gene and pelvic organ prolapse with
either fixed or random effects models**. *For both SNPs RefSNP alleles A/G. Plot presented as risk
associated with minor allele A. **Mantel-Haenszel fixed effects model (M-H)/DerSimonian and Laird
random effects model (DþL).
CI, confidence interval; OR, odds ratio.
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Research Gynecology ajog.orgepithelium and endopelvic fascia. The
available data on gene and protein
expression in pelvic tissue from women
with prolapse or stress incontinence are
heterogeneous but suggest increased
COL1A1 expression with reduced type 1
collagen content.40 Seven studies pro-
vided data on the rs1800012 SNP in as-
sociation with either POP or stress
incontinence, of which 6 could be in-
cluded in quantitative syntheses.
Five studies reported associations of
rs1800012 with anatomical POP in
Brazilian,41 Israeli,42 Polish,43 Italian,44
and Korean45 populations (Table 1).
The Korean study found only the wild
type GG allele among all 30 participants,
and could not be included in quantita-
tive synthesis. Despite each individual
study being underpowered, the pooled
effect size for the remaining 4 studies
was signiﬁcant (OR, 1.33; 95% CI,
1.02e1.73) (Figure 3) with low incon-
sistency.With limited information about
genotyping QC, and a possible risk of
population stratiﬁcation in 2 sam-
ples,41,42 we considered that bias could
not be fully excluded, providing Venice
grading BBB, or moderate epidemio-
logical credibility (Table 2).
Two studies of Polish46 and Greek47
women reported associations of the
same polymorphism with stress incon-
tinence, in both cases using a combined
symptomatic and objectively measured
case deﬁnition. The pooled effect size
was large (OR, 2.09; 95% CI, 1.35e3.22)
(Figure 3) with no heterogeneity (I2 ¼
0%). There was signiﬁcant deviation
from Hardy-Weinberg equilibrium in
one sample,46 suggesting signiﬁcant po-
tential for bias. However, exclusion of
this study would not change the result.
With high risk of bias the Venice grading
was CBC, or weak epidemiological
credibility (Table 2).
COL3A1
A large number of mutations in collagen,
type 3, alpha 1 have been associated
with vascular Ehlers-Danlos syndrome.
Inconsistent evidence suggests that uri-
nary incontinence and prolapse may be
prevalent among women with Ehlers-
Danlos.48 Collagen, type 3 has a particular
function in tissue repair, and is typically199.e10 American Journal of Obstetrics& Gynecoverexpressed in pelvic tissues from
women with prolapse.40 We identiﬁed
studies testing associations with 2
missense variants rs1800255 and
rs111929073, as well as 1 synonymous
SNP rs1801184. Both missense variants
had been tested in 2 studies, and therefore
could be combined in quantitative syn-
theses. Separate Taiwanese49 and Dutch50
studies found a nonsigniﬁcant pooled as-
sociation between rs1800255 and
anatomic prolapse (OR, 1.19; 95% CI,
0.88e1.61) (Figure 4), with no heteroge-
neity (Table 2).
For rs111929073, separate Korean51
and Brazilian52 samples demonstrated a
nonsigniﬁcant pooled effect (OR, 0.56;
95% CI, 0.19e1.61) (Figure 4) with high
heterogeneity (I2 ¼ 83.7%, P < .01).
Case deﬁnitions were similar for the 2
studies, making this an unlikely source of
heterogeneity. The primary Korean
study had suggested a large protective
effect of the minor allele, and theology FEBRUARY 2015heterogeneity between studies might
instead be explained by differences in
populations, or a simple Proteus effect.
LAMC1
Laminin gamma 1 is 1 of 3 kinds of
laminin chain that combine to make
different laminin isoforms. These
extracellular matrix glycoproteins are
an important constituent of basement
membranes, with roles in cell adhesion
and migration. LAMC1 was initially
proposed as a candidate gene for pro-
lapse in a linkage study of 9 individuals
from a family affected by early-onset
severe prolapse.53 We identiﬁed 3
further studies all from the United
States that attempted to replicate this
initial report of an association with
rs10911193,54-56 with all 3 including
testing of additional SNPs (Table 1).
All 3 individual studies found no as-
sociation for rs10911193, with a
nonsigniﬁcant pooled effect (OR, 1.13;
FIGURE 5
Forest plot of LAMC1 SNPs and prolapse
Forest plot of studies54-56 reporting associations among rs10911193, rs20563, and rs20558 single-
nucleotide polymorphisms (SNPs) of laminin gamma 1 gene and pelvic organ prolapse. *African
American subsample. **White subsample. rs10911193 RefSNP alleles C/T. Plot presented as risk
associated with minor allele T. rs20563 RefSNP alleles A/G. Plot presented as risk associated with
minor allele A. rs20558 RefSNP alleles C/T. Plot presented as risk associated with minor allele C.
CI, confidence interval; OR, odds ratio.
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ajog.org Gynecology Research95% CI, 0.83e1.53) (Figure 5) and no
heterogeneity. There was no evidence of
small study bias or publication bias.
Genotyping QC was generally well
documented for these studies, and pop-
ulation stratiﬁcation appropriately ac-
counted for. Two of the studies54,55
provided further data on rs20563 and
rs20558, 2 missense SNPs in near perfect
linkage disequilibrium, but again with
nonsigniﬁcant pooled effects (both OR,
1.12; 95% CI, 0.92e1.38) (Figure 5) and
no heterogeneity.
MMP1
Matrix metalloproteinase-1, also known
as interstitial collagenase, is one of a
number of enzymes that cleave collagen
type 1. The MMP1 gene is up-regulated
in pelvic tissues of women with pro-
lapse.40 Common variants of this gene
have been extensively studied in associ-
ation with chronic obstructive pulmo-
nary disease,57 cardiovascular disease,58
and a number of cancers including of
lung, colon, and breast. We identiﬁed 2
unpublished studies from the United
States,59,60 and 2 published studies of
Polish61,62 and Italian44 samples assess-
ing associations betweenMMP1 variants
and stress incontinence or prolapse. Of
these, 2 studies reported on rs1799750 in
association with prolapse,44,61 with a
nonsigniﬁcant pooled effect (OR, 0.97;
95% CI, 0.76e1.25) (Figure 6) with no
heterogeneity. One of the 2 studies
included demonstrated marked devia-
tion from Hardy-Weinberg equilibrium,
and exclusion of this study would how-
ever leave a single eligible study with a
nonsigniﬁcant association (OR, 0.88;
95% CI, 0.60e1.27).44 For the 2 studies
testing associations with SUI,60,61 the
pooled effect was again nonsigniﬁcant
(OR, 0.87; 95% CI, 0.63e1.20), with no
heterogeneity.
MMP3
Matrix metalloproteinase-3, also known
as stromelysin-1, is an enzyme that de-
grades a number of extracellular matrix
components including collagen type 3
and elastin. Similarly to MMP1, its
common variants have received most
research attention in association with
cardiovascular disease,58 and a numberof cancers. We identiﬁed 2 studies again
of women of European descent,44,61,62
both testing associations of rs3025058,
known as the 5A/6A promoter InDel,
with prolapse. The pooled effect was
again nonsigniﬁcant (OR, 1.11; 95% CI,
0.86e1.43) (Figure 7) with no
heterogeneity.
MMP9
Matrix metalloproteinase-9, also known
as 92-kDa type IV collagenase, degrades
collagen type 4 and type 5. Some evi-
dence suggests increased activation of
MMP9 in pelvic tissues from women
with prolapse.63 Like MMP1 and
MMP3, its common polymorphisms
have been linked to chronic obstructive
pulmonary disease,57 cardiovascular
disease,58 and some cancers. We identi-
ﬁed 4 studies of Italian,44 Taiwanese,64FEBRUARY 2015 Americand white US63,65 samples, assessing 10
different polymorphisms in association
with prolapse. Three studies contributed
to a metaanalysis of the rs17576 mis-
sense polymorphism. The pooled effect
was nonsigniﬁcant (OR, 1.02; 95% CI,
0.81e1.28) (Figure 8) but with signi-
ﬁcant heterogeneity (I2 ¼ 68.9%,
P ¼ .04). Case deﬁnitions were similar
for the 3 studies, making this an unlikely
source of heterogeneity. All studies
demonstrated Hardy-Weinberg equilib-
rium, and we judged a low risk of pop-
ulation stratiﬁcation. The single study
among Asian women64 suggested a
narrowly signiﬁcant effect (OR, 0.62;
95% CI, 0.40e0.98), while subgroup
analysis of the 2 white US samples
showed no pooled effect (OR, 1.22; 95%
CI, 0.93e1.60). Two studies contributed
to metaanalysis of rs3918242, withan Journal of Obstetrics& Gynecology 199.e11
FIGURE 6
Forest plot of rs1799750 SNP of MMP1
Forest plot of studies44,60,61 reporting associations between rs1799750* single-nucleotide poly-
morphism (SNP) of matrix metalloproteinase 1 (MMP1) gene and either stress urinary incontinence
(SUI) or pelvic organ prolapse (POP) with either fixed or random effects models. *RefSNP Alleles -/G.
Plot presented as risk associated with minor deletion allele.
CI, confidence interval; OR, odds ratio.
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FIGURE 7
Forest plot of rs3025058 SNP of MMP3 and prolapse
Forest plot of studies6,44 reporting associations between rs3025058* single-nucleotide poly-
morphism (SNP) of matrix metalloproteinase 3 gene and pelvic organ prolapse. *RefSNP Alleles -/T.
Plot presented as risk associated with minor deletion allele.
CI, confidence interval; OR, odds ratio.
Cartwright. Genetic association studies of LUTS and POP. Am J Obstet Gynecol 2015.
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CI, 0.83e1.89) (Figure 8) and no
heterogeneity.
Publication bias and selective
analysis
Each metaanalysis included at most 4
studies or subgroups, providing low
power for conventional measures of
funnel plot asymmetry. The Harbord
test demonstrated no evidence of small
study bias or publication bias (all P > .1).
We applied the signiﬁcance chasing bias
test,30 to look for further evidence of
publication bias or selective outcome
reporting. This exploratory test is used
to detect an excess of signiﬁcant results,
either within a single metaanalysis, or in
a whole domain of research. In common
with other tests of publication bias, P < .1
is usually taken as the threshold for sig-
niﬁcance. We applied the test across each
of the 13 metaanalyses conducted indi-
vidually, and for the 13 considered
together as 1 domain. Given the power of
the individual studies to detect the
observed pooled effect sizes in each
metaanalysis, across the domain as a
whole we expected 6.61 statistically sig-
niﬁcant studies, and observed 7 signiﬁ-
cant studies in our own prespeciﬁed
reanalyses using the allelic test (P ¼ .87).
However, primary publications applied a
variety of analytic techniques, and from
the set of studies included in meta-
analysis we observed 11 studies report-
ing statistically signiﬁcant results in their
own analyses (P ¼ .14), typically using
alternative models of inheritance. These
ﬁndings are suggestive primarily of se-
lective analysis, rather than publication
bias. Individual metaanalyses again
provided limited power for this test, but
possible bias was most apparent in the
quantitative synthesis of association of
prolapse with the rs17576 SNPofMMP9
(P ¼ .11).
Genes and/or polymorphisms
reported in a single study
Among the included studies, some
had assessed associations with poly-
morphisms for which no replication has
been reported. Statistically signiﬁcant asso-
ciations have been suggested between pro-
lapse and the rs2228480 polymorphism of
FIGURE 8
Forest plot of MM9 SNPs and prolapse
Forest plot of studies44,63-65 reporting associations between rs3918242* and rs17576** single-
nucleotide polymorphisms (SNPs) of matrix metalloproteinase 9 gene and pelvic organ prolapse
with either fixed or random effects models⌘. *rs3918242 RefSNP alleles C/T. Plot presented as risk
associated with minor allele T. **rs17576 RefSNP alleles A/G. Plot presented as risk associated with
minor allele A.⌘Mantel-Haenszel fixed effects model (M-H)/DerSimonian and Laird random effects
model (DþL).
CI, confidence interval; OR, odds ratio.
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ajog.org Gynecology ResearchESR1, the estrogen receptor alpha66; be-
tween prolapse and certain haplotypes of
ESR2, the estrogen receptor beta67; be-
tween prolapse and the rs484389 poly-
morphism of PGR, the progesterone
receptor68; between prolapse and the
rs10478694 polymorphism of EDN1,
endothelin 169; between incontinence
and the CAG copy number variant of
AR, the androgen receptor70; between
incontinence and the rs6313 poly-
morphism of HTR2A, the serotonin 2A
receptor71; between stress incontinence
and both the rs2165241 and rs1048661
variants of LOX-L1, lysyloxidaselike-172;
between the rs1136410 polymor-
phism of poly-ADP ribose polymerase
(PARP)73 and prolapse; and ﬁnally be-
tween the rs1695 polymorphism of
glutathione S-transferase pi (GSTP1)
and prolapse.74 We found only 1 pub-
lished study reporting entirely nonsig-
niﬁcant results,75 further suggesting a
high probability of selective outcome
reporting or publication bias for this
ﬁeld of study as a whole. Following the
Venice recommendations,28 we a priori
assigned all nominally signiﬁcant but
unreplicated associations weak epide-
miological credibility. Three genome-
wide association studies (GWAS) have
now been reported for incontinence or
prolapse.76-78 Of note, none of these
suggested candidates for prolapse or
incontinence, including both those
from single studies, as well as those
included in metaanalyses, were identi-
ﬁed in these genome-wide analyses.
Across the 3 GWAS, SNPs at 9 inde-
pendent loci have reached genome-wide
signiﬁcance (P < 5  10-8) (Table 1) in
discovery cohorts, although replication
of these candidate loci has not been
demonstrated.
COMMENT
Strengths and limitations
The strengths of this review include a
comprehensive search of both published
and unpublished studies, applying
explicit criteria to potentially eligible
studies, and employing standardized,
piloted data forms for data collection,
guided by written instructions, and an
unbiased assessment and synthesis of
reported associations. We followed aprespeciﬁed data analysis plan, and
contacted authors for clariﬁcations and
additional data.
Among the challenges faced in this
review was the inclusion of studies with
varying diagnostic criteria. There may be
considerable disparity between symp-
tomatic and objective ﬁndings for both
LUTS and prolapse, and despite long-
standing efforts for standardization2
diagnostic criteria are not widely agreed
upon. Despite this caution, we found
that the literature had used largely
concordant deﬁnitions. From the pro-
lapse studies, 2 studies had used a pro-
lapse case deﬁnition based on need for
surgical treatment, but all others used an
accepted anatomic staging system, typi-
cally POP Quantiﬁcation. There was also
little variation in cutoffs for signiﬁcant
prolapse, with almost all studies con-
sidering prolapse stage 0 or stage 1 as
normal/control. Both overactive bladder
studies included in metaanalysis used aFEBRUARY 2015 Americcombination of self-reported symptoms,
with 3-day bladder diary for diagnosis.
Similarly both SUI studies included in
metaanalysis used a combination of
cystometry and pad testing for diagnosis.
This is reﬂected in a lack of heterogeneity
in most metaanalyses. Regardless of the
presence of statistical heterogeneity,
there remains potential for bias toward
the null from heterogeneity in case
deﬁnitions.
It is evident that overactive bladder in
particular may have multiple underlying
causes,79,80 and these syntheses may
therefore include participants with
diverse underlying etiologies for their
symptoms. The largest metaanalyses
possible still include <1000 participants
in total, and therefore provide adequate
power only for associations with large
effect size (approximately OR, 0.6 or
OR, 1.8). It is both likely that smaller
effect sizes have been missed in these
syntheses, and highly probable thatan Journal of Obstetrics& Gynecology 199.e13
Research Gynecology ajog.orgpolymorphisms with larger effect sizes
are still to be discovered.
Future work
Future advances are likely within the
context of GWAS using large-scale pop-
ulation-based cohorts phenotyped for
these conditions. The discovery of fur-
ther causative variants should both help
to explain the complex pathophysiology
of these conditions, and provide poten-
tially a route to effective prevention and
treatment.
Conclusions
Family and twin studies have provided
convincing evidence for genetic predis-
position to incontinence, prolapse, and
overactive bladder, with genetic varia-
tion contributing up to half of pop-
ulation phenotypic variability. These
metaanalyses provide moderate epide-
miological credibility for associations of
variation in ADRB3 with overactive
bladder, and COL1A1 with prolapse.
As for all complex diseases, these 2
currently identiﬁed polymorphisms
explain a tiny fraction of that phenotypic
variation. The widespread availability of
direct-to-consumer testing means that
some patients may present with ques-
tions about the implications of these
polymorphisms. However, testing for
any of these SNPs cannot be recom-
mended based on current evidence.
Nevertheless, clinicians and researchers
should be aware of the putative risks
associated with these SNPs, and the un-
certainty regarding potential biases in
the primary studies. In the future, ge-
netic counseling may play one part of
advice about risks of mode of delivery,
and may help target women for primary
or secondary prevention. Currently, cli-
nicians should continue to use a family
history of prolapse or incontinence as a
simple marker of future risk, with clearly
documented interactions with modiﬁ-
able risk factors such as vaginal
childbirth and obesity. -REFERENCES
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Summary of interim Venice guideline ratings of credibility of genetic
associations
Strong credibility for association requires AAA rating. Any B rating confers maximum moderate
credibility, while any C rating confers weak credibility.
Adapted and abridged from Ioannidis et al.29
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SUPPLEMENTARY TABLE 1
Functional annotation of investigated genes
Official gene
symbol Gene name(s) No. of studies included Molecular function(s)
ADRA1A Adrenergic, alpha-1A-, receptor 1 Adrenoceptor activity
Alpha-adrenergic receptor activity
Alpha1-adrenergic receptor activity
Amine receptor activity
ADRB3 Adrenergic, beta-3-, receptor 3 Adrenoceptor activity
Beta-adrenergic receptor activity
Amine receptor activity
Beta-3-adrenergic receptor activity
Adrenergic receptor binding
Beta-3 adrenergic receptor binding
Identical protein binding
Protein homodimerization activity
Amine binding
Alcohol binding
Protein dimerization activity
Epinephrine binding
Norepinephrine binding
AR Androgen receptor 1 DNA binding
Transcription factor activity
Steroid hormone receptor activity
Ligand-dependent nuclear receptor activity
Androgen receptor activity
Steroid binding
Androgen binding
Zinc ion binding
Lipid binding
Transcription activator activity
Transcription regulator activity
Hormone binding
Ion binding
Cation binding
Sequence-specific DNA binding
Metal ion binding
Transition metal ion binding
Protein dimerization activity
COL1A1 Collagen, type I, alpha 1 7 Structural molecule activity
Extracellular matrix structural constituent
Growth factor binding
Identical protein binding
Platelet-derived growth factor binding,
COL3A1 Collagen, type III, alpha 1 4 Integrin binding
Structural molecule activity
Extracellular matrix structural constituent
Growth factor binding
Protein complex binding
SMAD binding
Platelet-derived growth factor binding
COL18A1 Collagen, type XVIII, alpha 1 1 Structural molecule activity
Extracellular matrix structural constituent
Zinc ion binding
Ion binding
Cation binding
Metal ion binding
Transition metal ion binding
Cartwright. Genetic association studies of LUTS and POP. Am J Obstet Gynecol 2015. (continued)
Research Gynecology ajog.org
199.e18 American Journal of Obstetrics& Gynecology FEBRUARY 2015
SUPPLEMENTARY TABLE 1
Functional annotation of investigated genes (continued)
Official gene
symbol Gene name(s) No. of studies included Molecular function(s)
CPE Carboxypeptidase E 1 Metallocarboxypeptidase activity
Zinc ion binding
CYP17A1 Cytochrome P450, family 17,
subfamily A, polypeptide 1
1 Steroid 17-alpha-monooxygenase activity
Iron ion binding
Steroid hydroxylase activity
Electron carrier activity
Oxygen binding
Heme binding
Ion binding
Cation binding
Metal ion binding
Tetrapyrrole binding
Transition metal ion binding
CYP19A1 Cytochrome P450, family 19,
subfamily A, polypeptide 1
1 Iron ion binding
Electron carrier activity
Oxidoreductase activity
Oxygen binding
Heme binding
Ion binding
Cation binding
Metal ion binding
Tetrapyrrole binding
Transition metal ion binding
Aromatase activity
EDN1 Endothelin 1 1 Hormone activity
Bombesin receptor binding
Endothelin A receptor binding
Endothelin B receptor binding
ESR1 Estrogen receptor 1 1 DNA binding
Transcription factor activity
Steroid hormone receptor activity
Ligand-dependent nuclear receptor activity
Steroid binding
Zinc ion binding
Lipid binding
Promoter binding
Nitric-oxide synthase regulator activity
Estrogen receptor activity
Transcription regulator activity
Estrogen response element binding
Hormone binding
Ion binding
Cation binding
Sequence-specific DNA binding
Metal ion binding transition
Metal ion binding
Protein N-terminus binding
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SUPPLEMENTARY TABLE 1
Functional annotation of investigated genes (continued)
Official gene
symbol Gene name(s) No. of studies included Molecular function(s)
ESR2 Estrogen receptor 2 (ER beta) 1 DNA binding
Transcription factor activity
Steroid hormone receptor activity
Transcription cofactor activity
Transcription coactivator activity
Ligand-dependent nuclear receptor activity
Steroid binding transcription factor binding
Zinc ion binding
Lipid binding
Transcription activator activity
Estrogen receptor activity
Transcription regulator activity
Receptor regulator activity
Receptor inhibitor activity
Hormone binding
Ion binding
Cation binding
Sequence-specific DNA binding
Metal ion binding
Transition metal ion binding
Receptor antagonist activity
GSTM1 Glutathione S-transferase mu 1 1 Glutathione transferase activity
GSTP1 Glutathione S-transferase pi 1 1 Glutathione transferase activity
GSTT1 Glutathione S-transferase theta 1 1 Glutathione transferase activity
HTR2A 5-Hydroxytryptamine
(serotonin) receptor 2A
1 Serotonin receptor activity
Amine receptor activity
Protein complex binding
Amine binding
Serotonin binding
LAMC1 Laminin, gamma 1 (formerly LAMB2) 3 Structural molecule activity
Extracellular matrix structural constituent,
LOXL1 Lysyl oxidase-like 1 3 Copper ion binding
Oxidoreductase activity
Ion binding
Cation binding
Metal ion binding
Transition metal ion binding
MMP1 Matrix metallopeptidase 1
(interstitial collagenase)
5 Endopeptidase activity
Metalloendopeptidase activity
Calcium ion binding
Peptidase activity
Metallopeptidase activity
Zinc ion binding
Ion binding
Cation binding
Metal ion binding
Transition metal ion binding
Peptidase activity
Acting on L-amino acid peptides
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SUPPLEMENTARY TABLE 1
Functional annotation of investigated genes (continued)
Official gene
symbol Gene name(s) No. of studies included Molecular function(s)
MMP10 Matrix metallopeptidase 10
(stromelysin 2)
1 Endopeptidase activity
Metalloendopeptidase activity
Calcium ion binding
Peptidase activity
Metallopeptidase activity
Zinc ion binding
Ion binding
Cation binding
Metal ion binding
Transition metal ion binding
Peptidase activity
Acting on L-amino acid peptides
MMP11 Matrix metallopeptidase 11
(stromelysin 3)
1 Endopeptidase activity
Metalloendopeptidase activity
Calcium ion binding
Peptidase activity
Metallopeptidase activity
Zinc ion binding
Ion binding
Cation binding
Metal ion binding
Transition metal ion binding
Peptidase activity
Acting on L-amino acid peptides
MMP2 Matrix metallopeptidase 2
(gelatinase A, 72-kDa gelatinase,
72-kDa type IV collagenase)
1 Endopeptidase activity
Metalloendopeptidase activity
Calcium ion binding
Peptidase activity
Metallopeptidase activity
Zinc ion binding
Ion binding
Cation binding
Metal ion binding
Transition metal ion binding
Peptidase activity
Acting on L-amino acid peptides
MMP3 Matrix metallopeptidase 3
(stromelysin 1, progelatinase)
3 Endopeptidase activity
Metalloendopeptidase activity
Calcium ion binding
Peptidase activity
Metallopeptidase activity
Zinc ion binding
Ion binding
Cation binding
Metal ion binding
Transition metal ion binding
Peptidase activity
Acting on L-amino acid peptides
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SUPPLEMENTARY TABLE 1
Functional annotation of investigated genes (continued)
Official gene
symbol Gene name(s) No. of studies included Molecular function(s)
MMP8 Matrix metallopeptidase 8
(neutrophil collagenase)
1 Endopeptidase activity
Metalloendopeptidase activity
Calcium ion binding
Peptidase activity
Metallopeptidase activity
Zinc ion binding
Ion binding
Cation binding
Metal ion binding
Transition metal ion binding
Peptidase activity
Acting on L-amino acid peptides
MMP9 Matrix metallopeptidase 9
(gelatinase B, 92-kDa gelatinase,
92-kDa type IV collagenase)
4 Endopeptidase activity
Metalloendopeptidase activity
Calcium ion binding
Peptidase activity
Metallopeptidase activity
Zinc ion binding
Ion binding
Cation binding
Metal ion binding
Transition metal ion binding
Peptidase activity
Acting on L-amino acid peptides
PARP1 Poly (ADP-ribose) polymerase 1 1 Telomere maintenance
DNA repair
Transcription
Chromosome organization
PGR Progesterone receptor 1 DNA binding transcription factor activity
Steroid hormone receptor activity
Ligand-dependent nuclear receptor activity
Steroid binding
Zinc ion binding
Lipid binding
Transcription regulator activity
Ion binding
Cation binding
Sequence-specific DNA binding
Metal ion binding
Transition metal ion binding
Protein N-terminus binding
PRCP Prolylcarboxypeptidase
(angiotensinase C)
1 Carboxypeptidase activity
Serine hydrolase activity
TIMP1 TIMP metallopeptidase inhibitor 1 1 Enzyme inhibitor activity,
Endopeptidase inhibitor activity
Metalloendopeptidase inhibitor activity
Metalloenzyme regulator activity
Peptidase inhibitor activity
Metalloenzyme inhibitor activity
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SUPPLEMENTARY TABLE 1
Functional annotation of investigated genes (continued)
Official gene
symbol Gene name(s) No. of studies included Molecular function(s)
TIMP3 TIMP metallopeptidase inhibitor 3 1 Enzyme inhibitor activity
Endopeptidase inhibitor activity
Metalloendopeptidase inhibitor activity
Metalloenzyme regulator activity
Peptidase inhibitor activity
Metalloenzyme inhibitor activity
ZFAT Zinc finger and AT hook
domain containing
1 DNA binding
Zinc ion binding
Ion binding
Cation binding
Metal ion binding
Transition metal ion binding
Functions assigned from http://david.abcc.ncifcrf.gov.
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SUPPLEMENTARY TABLE 2
Overrepresented Gene Ontology biological processes among investigated genes
Biological process GO term Description Genes
1 GO:0030574 Collagen catabolic process MMP1 MMP2 MMP3 MMP8 MMP9 MMP10 MMP11
2 GO:0005578 Proteinaceous extracellular matrix LOXL1 MMP1 MMP2 MMP3 MMP8 MMP9 MMP10
MMP11 TIMP1
3 GO:0006508 Proteolysis CPE MMP1 MMP2 MMP3 MMP8 MMP9 MMP10
MMP11 PRCP
4 GO:0008152 Metabolic process CPE GSTM1 MMP2 MMP8 MMP3 GSTP1 MMP1
MMP10 MMP9
5 GO:0005576 Extracellular region COL1A1 COL3A1 CPE EDN1 ESR2 LAMC1 LOXL1
MMP1 MMP2 MMP3 MMP8 MMP9 MMP10 MMP11
TIMP1 COL18A1
6 GO:0007267 Cell-cell signalling PGR AR ADRA1A ESR2 EDN1
7 GO:0005615 Extracellular space AR COL1A1 COL3A1 EDN1 LAMC1 LOXL1 MMP2
MMP3 MMP8 MMP9 MMP10 COL18A1
8 GO:0008270 Zinc ion binding ESR1 ESR2 MMP1 MMP2 MMP3 MMP8 MMP9 MMP10
MMP11 PGR ZFAT
All processes significant at P < .01, analysis using http://webclu.bio.wzw.tum.de/profcom/. Overrepresented Gene Ontology: http://www.geneontology.org.
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